Cetuximab in Early-Stage Colon Cancer Shows No Benefit - National Cancer Institute

Links shared publicly online about this topic.

  • 1,559
    total visits

Cetuximab in Early-Stage Colon Cancer Shows No Benefit - National Cancer Institute

cancer.gov —

A Data Monitoring Committee (DMC) determined that in a phase 3 clinical trial for early-stage colon cancer, no group of patients benefited from the addition of the monoclonal antibody cetuximab (ErbituxTM) to a standard chemotherapy regimen known as FOLFO

View full resource at cancer.gov

Tags: Cancer, Chemotherapy, Colon Cancer, Phase 3 Clinical Trial, Clinical Trial, Erbitux

  • Share

Most Recently Shared on December 3, 2009 at 7:01 am By:

DrOncol Noushin Hart MD

RT @NCIMedia NCI News: Addition of Cetuximab 2 Standard Chemo 4 Early-Stage Colon Cancer Shows No Benefit-Phase 3 Trial http://j.mp/8eqZP3

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

NCI Media Relations NCI Media Relations

Advertisement